UBS AM
ARCT icon

UBS AM’s Arcturus Therapeutics ARCT Stock Holding History

UBS AM’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12K Hold
1,787
– – ﹤0.01% 3227
2026
Q1 		$13.8K Buy
1,787
+687
+62% +$5.01K ﹤0.01% 3229
2025
Q4 		$6.74K Buy
+1,100
New +$11.9K ﹤0.01% 2926
2025
Q2 		– Sell
-47,452
Closed -$503K – 2624
2025
Q1 		$503K Sell
47,452
-4,737
-9% -$75.2K ﹤0.01% 2502
2024
Q4 		$886K Sell
52,189
-153,567
-75% -$2.89M ﹤0.01% 2419
2024
Q3 		$4.78M Buy
205,756
+204
+0.1% +$4.36K ﹤0.01% 1595
2024
Q2 		$5.01M Buy
205,552
+25,154
+14% +$763K ﹤0.01% 1486
2024
Q1 		$6.09M Buy
180,398
+154,444
+595% +$5.47M ﹤0.01% 1171
2023
Q4 		$818K Buy
25,954
+2,707
+12% +$64.3K ﹤0.01% 2131
2023
Q3 		$594K Buy
23,247
+6,352
+38% +$196K ﹤0.01% 2223
2023
Q2 		$405K Hold
16,895
– – ﹤0.01% 2386
2023
Q1 		$405K Buy
+16,895
New +$303K ﹤0.01% 2386
2022
Q2 		– Sell
-17,692
Closed -$477K – 2694
2022
Q1 		$477K Hold
17,692
– – ﹤0.01% 2479
2021
Q4 		$655K Sell
17,692
-1,253
-7% -$51.1K ﹤0.01% 2431
2021
Q3 		$905K Buy
18,945
+269
+1% +$12.1K ﹤0.01% 2221
2021
Q2 		$632K Buy
18,676
+2,451
+15% +$83K ﹤0.01% 2442
2021
Q1 		$670K Buy
16,225
+1,625
+11% +$96.9K ﹤0.01% 2278
2020
Q4 		$633K Buy
14,600
+300
+2% +$20.3K ﹤0.01% 2206
2020
Q3 		$613K Buy
14,300
+3,200
+29% +$159K ﹤0.01% 2042
2020
Q2 		$519K Buy
+11,100
New +$383K ﹤0.01% 2117

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

UBS AM's ARCT Position: Q2 2026 in Review

UBS AM held its Arcturus Therapeutics (ARCT) position steady in Q2 2026 at 1,787 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #3227.

UBS AM first reported a position in ARCT in Q2 2020 and has held it in 20 quarters since. The position peaked at $6.09M in Q1 2024. 134 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • UBS AM held 1,787 shares of Arcturus Therapeutics worth $12K as of Q2 2026.
  • UBS AM left its Arcturus Therapeutics share count unchanged in Q2 2026.
  • Arcturus Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3227 holding.
  • UBS AM first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 20 quarters since.
  • UBS AM's Arcturus Therapeutics position peaked at $6.09M in Q1 2024.
  • 134 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.